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The growth and proliferation of mammalian cells are controlled in part by 
polypeptide hormones found in the serum. Malignant or transformed cells 
appear to require no or lower concentrations of growth-controlling factor(s) as 
compared with normal or untransformed cells. It has therefore been suggested 
that cells could become malignant via the aberrant production of polypeptide 
growth-controlling factor(s) acting in an autocrine manner through functional 
cell membrane receptors resulting in uncontrolled proliferation. Recently, the 
“autocrine hypothesis” has been further defined in that malignant transformation 
may be the result not only from excessive production, expression, and action of 
positive autocrine growth factors but also the failure of cells to synthesize, 
express or respond to specific negative growth factors that they normally 
release to control their own growth. 
It had been shown that the T helper cell line DIO secretes large amounts 
of a T cell growth factor, believed to be 1L-2, upon crosslinking of its antigen- 
class II MHC products receptor yet failed to proliferate. However, if the 
monokine IL-1 was present during stimulation potent proliferation occurred. 
Furthermore, DIO cells have to been shown to both respond to IL-2 derived 
from a T cel! hybridoma and to express functional IL-2 receptors. Thus in the 
presence of both functional T cell growth factor and IL-2 receptors this clone 
fails to proliferate. 

It appears that there are at least two possible explanations of why DIO 
fails to proliferate in response to crosslinking of its antigen-class II MHC 
products receptor. The first explanation is that DIO does not secrete IL-2 but IL- 
4. DIO cells do not respond vigorously to purified IL-4, probably because the 
cells do not express significant numbers of IL-4 receptors. However, if IL-1 and 
IL-4 are incubated together with DIO cells, the cells are able to proliferate in 
response to IL-4. Secondly, in addition to IL-4, DIO produces an inhibitor of T 
cell responses to IL-2 and possibly IL-4. Although the relative contribution each 
plays has yet to be definitively determined, the initial evidence suggests that the 
IL-1 dependence of DIO's autocrine growth is largely if not entirely due to the 
requirement for IL-1 as a cofactor for IL-4 driven T cell growth. The precise 
mechanisms of this IL-1 dependence is currently being studied. 
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Although many of the advances in immunology have occurred in the past 
twenty years, references to the immune system and immunology can be found 
dating back to the bible and before. Thucydides, in his description of the plague 
that struck Athens in 430 b. c. noted: “Yet it was with those who had recovered 
from the disease that the sick and the dying found most compassion. These 
knew what it was from experience, and had now no fear for themselves; for the 
same man was never attacked twice-never at least fatally.”1 In describing the 
plague of the Byzantine emperor Justinian a thousand years later, Procopius 
said “at a later time it [the plague] came back; then those who dwelt round about 
this land, whom formerly it had afflicted most sorely, it did not touch at all.”1 In 
time this resistance to reinfection become known as immunity, from the Latin 
immunitas 2 
It was not until the late 19th century when the importance of cells was 
finally appreciated that immunology became a true science. Before that time, 
medicine had been under the domination of the old Greek view that disease 
was based on imbalances in the “essential bodily humors.” Metchnikoff, based 
on his observations of phagocytic cells in marine invertebrates, suggested that 
vertebrate phagocytic cells performed a similar protective function3. Shortly 
after the initial description of the phagocytic theory, it came under severe and 
protracted attack with the fiercest criticism coming from Baumgarten3. At about 
the same time, Nuttall noted that the serum of normal animals contained 
substances which were toxic to certain microorganisms, eg. bacteria, and 
whose properties were enhanced when the host was immunized1. In 1890 von 
Behring and Kitasato described humoral immunity to diphtheria and tetanus1- 
With this and other published reports, the humoral theory of immunology gained 

2 
converts while supporters of the cellular theory dwindled. It was not until 
Medawar's observations on tissue transplantation and immunologic tolerance, 
Burnet's emphasis on the importance of cells in antibody production, and 
descriptions on the role of the thymus in immunologic deficiency states in the 
1950s and 1960s that a renewed interest cellular immunology finally occurred1. 
Brief Overview 
The immune system has classically been divided into cell mediated and 
humoral components. Humoral immunity is provided by antibodies that 
circulate in the serum and in the lymphatic fluid. Cellular immunity, as its name 
implies, is provided by specific cells in the immune system. Although there is 
much overlap between the two “arms,” for descriptive purposes it is still relevant 
to talk in these terms. People with deficiencies in humoral immunity are 
plagued with recurrent or chronic sinopulmonary infections, meningitis, and 
bacteremias caused by pyogenic bacteria while abnormalities in cell mediated 
immunity predisposes individuals to disseminated viral and fungal as well as 
protozoal infections4. 
The constituents of the immune system include lymphocytes, 
macrophages and their related cells, eg. dendritic cells of the spleen, Kupffer 
cells of the liver, epithelial Langerhans cells, etc., and specialized epithelial 
cells, such as those found in the thymus5. These cells may be found in 
organized tissues and organs, such as the lymph nodes, the spleen, the tonsils, 
the Peyer's patches of the intestine, the thymus, and the bone marrow or may 
circulate throughout the body in the blood and in the lymphatic fluid5. 
There are two major classes of lymphocytes: B lymphocytes which are 
the precursors of antibody secreting plasma cells and T lymphocytes which are 
thymus dependent and mediate important regulatory functions including 
augmentation and suppression of the immune response and antibody 
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production5. Both B lymphocytes and T lymphocytes are derived from 
hematopoietic stem cells located within the bone marrow and in other 
hematopoietic tissue. Mononuclear phagocytes are the third type of cell that is 
intimately involved in the development and expression of humoral and cell- 
mediated immunity6. These cells participate in a number of events in the 
immune response including host defense against microorganisms, cellular 
interactions with lymphocytes, and secretion of monokines6. 
ANTIGEN PRESENTING CELLS 
The first step that occurs when a foreign material (antigen) enters the 
body is its uptake by cells of the phagocytic system, usually by 
nonimmunological means6. Antigen is then processed by the cell such that an 
antigen fragment7 or native antigen8 is present on the surface of the antigen 
presenting cell (APC). Antigen in association with self class II major 
histocompatibility complex (MHC) products is then presented to the T cell 
receptor complex9. This in turn, leads to T cell activation, proliferation10 and 
production of various T cell lymphokines, primarily T cell growth factor 
(TCGF)11. 
Currently, there is much controversy over which cell type or types present 
antigen in vivo. A number of different cell types have been reported in the 
literature: peritoneal and splenic macrophages12, splenic dendritic cells13, 
epidermal Langerhan cells14, Kupffer cells15, alveolar macrophages16, B 
cells17, and B cell tumors18. Each, under the appropriate experimental 
conditions, are able to act as APCs. The biological significance of all these 





T lymphocytes (or T cells), so called because their maturation requires 
processing in the thymus19, are the central cells in the cellular immune 
response. They generate cytotoxic responses to alloantigens, exert helper and 
suppressor effects on the production of antibodies, and initiate graft versus host 
responses20. Cantor and Boyse, in a series of elegant experiments, 
demonstrated that commitment of T cells to participate exclusively in either 
helper or cytotoxic function is a differentiative process that takes place before 
they encounter antigen20. They further showed that T cells involved in helper 
responses expressed different surface antigens (Ly-1+2_) than those involved in 
killing allogeneic target cells (Ly-1‘2+)20. Cantor and Boyse also noted that Ly- 
1+2‘T cells recognized self class II MHC products while Ly-I'2+T cells 
recognized self class I MHC products21. Rao et al. confirmed the initial 
observation of Cantor and Boyse by using 21 T cell clones derived from mixed 
lymphocyte cultures and studying the association of Ly phenotype with function 
and specificity for MHC products22. 
As mentioned above, antigen together with class II MHC products are 
presented by APCs to T helper cells. This in turn results in proliferation and 
elaboration of a variety of lymphokines. The T helper cell binds the antigen-self 
class II MHC complex through its receptor, a hetrodimer composed of a disulfide 
linked acidic (a) and basic ((3) chains23. Although the antigen-self class II MHC 
complex is the apparent ligand for the T cell receptor, it appears that receptor 
cross linking or aggregation is the necessary requirement for T cell activation24. 
In addition to receptor cross linking it has been shown that certain T cells 
require interleukin 1 (IL-1) for the secretion of T cell lymphokines, mainly 
. 
5 
interleukin 2 (IL-2)25-26; while, in other T cells IL-1 was required for the 
expression of IL-2 receptors27. However Malek et al., using a heterogeneous 
population of resting T helper cells essentially depleted of accessory cells, 
found that IL-1 neither induced IL-2 secretion nor promoted IL-2 receptor 
expression28. 
Activation 
In addition to activation via antigen and self class II MHC products, T 
helper cells may be activated with plant lectins such as phytohemagglutinin 
(PHA) and concanavalin A (Con A)29, calcium ionophores such as A2318730, 
and monoclonal antibodies31-32,33,34 
The term lectin refers to a large collection of carbohydrate binding 
multimeric glycoproteins derived from plant and animal sources35. There are at 
least several hundred plant extracts that interact with and agglutinate 
erythrocytes; however, only a small number bind to lymphocytes and induce a 
mitogenic response36. Of these PHA from the red kidney bean (Phaseola 
vulgaris) and Con A from the jack bean (Canavalia ensiformis) are the most 
widely used T cell lectins36. Although the mechanism by which lectins interact 
with cell surface proteins remains largely unknown, they apparently work by 
cross-linking cell surface molecules29. In a recent study, Tsien et al. have 
partially unraveled the mechanism of lectin induced activation with their finding 
of increased intracellular calcium following lectin binding37. 
Calcium ionophores, such as A23187, work by directly inserting into the 
plasma membrane forming a calcium ion channel which results in a rapid influx 
of calcium38. Akerman and Andersson, using purified human T cells, showed 
polyclonal proliferation following treatment with A2318730. This finding 
combined with those of Tsien et al. suggest that an increase in cytosolic calcium 
directly triggers the proliferative response. 
. 
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Monoclonal antibodies directed at the T cell receptor complex have 
allowed further definition of the mechanism involved in activation of T cells31'34. 
Kaye et al. described a monoclonal antibody (3D3) specific for the cloned 
helper T cell line D10.G4.1 (DIO) that completely replaced the requirement for 
antigen and self class II MHC products in the activation of that clone24'34. 
Using the Fab fragment from that monoclonal antibody as an inhibitor of 
activation, activation of DIO by either antigen-self class II MHC products or 
allogeneic class II MHC products was blocked. The ability of the Fab fragment 
to induce proliferation was restored when anti-mouse immunoglobulin was 
used to cross link the Fab fragments. They also noted that the ability of 3D3 to 
activate DIO was dependent on a signal from an accessory cell and that by 
using either IL-1 or IL-2 the requirement for accessory cells could eliminated. 
(Note: The source of IL-2 used in those experiments has recently been shown to 
contain an additional TCGF, see results). The conclusions to be drawn from 
these experiments are (1) the T cell receptor complex is the binding site for both 
antigen-self class II MHC products and allogeneic-class II MHC products, (2) 
receptor cross linking and not receptor occupancy provides the necessary 
signal for activation , and (3) activation for T cell growth is a two signal process. 
Classification of T Helper Cells 
Murine T helper cells appear to be fairly uniform when viewed in the 
context of surface markers such as Ly-1; however, when assessed by functional 
criteria at least two39’40’41’42 and as many as four43 different types of T helper 
cells have been described. Mosmann et al. screening a large panel of antigen- 
specific murine T helper cell clones found that two types of functionally distinct 
cells could be distinguished based on lymphokine secretion44. Mosmann Type 
1 T helper cells when stimulated with antigen and APCs or Con A produced IL- 
2, interferon-y (IFN-y), granulocyte-macrophage colony stimulating factor (GM- 
. 
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CSF), and interleukin 3 (IL-3) while Mosmann Type 2 cells secreted IL-3 and 
interleukin 4 (IL-4). Kim et al.; however, divided Lyl+2‘ cells into four 
functionally distinct types based upon their ability to induce a 
phosphorylcholine-specific (PC) plaque-forming cell response, their 
requirement for the presence of antigen during induction of B cell responses, 
and their activation of T15-bearing or non-TI 5-bearing B cells43. (T15 is the 
prototypic idiotypic determinant characteristic of the BALB/c PC-binding 
myeloma protein TEPC-15)45. Types 1 and 2 induce B cells to secrete anti-PC 
antibodies in an antigen specific class ll-MHC products restricted fashion. Type 
3 cells induce antigen-specific class ll-MHC products restricted B cell 
proliferation, but do not lead to specific antibody formation, and Type 4 cells are 
autoreactive and induce antigen-independent B cell activation and antibody 
secretion. Killar et al. have recently confirmed the finding that IL-4 producing T 
cell lines do not secrete IL-2, IFN-y, and lymphotoxin46. They have further 
shown that activation of antigen-specific B cells by T helper cells appears to 




Lymphokines are non-antigen-specific, hormone-like polypeptides 
produced by cells of the immune system47. They include interleukins, 
interferons, hematopoietic colony-stimulating factors, macrophage-modulating 
factors, and chemotactic factors48. Although they perform many diverse 
functions, most can be grouped into one of four categories: growth factors, 
activation and/or differentiation factors, lymphotoxins, and chemotactic 
factors47. These categories are by no means mutually exclusive in that it is 
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possible for a lymphokine to have more than one function; for example, IL-4 
both activates resting B cells49 and promotes the growth of certain T helper cell 
lines50. Like the hormones of the endocrine system, lymphokines are active in 
concentrations ranging from 10‘10 to 10'12m48 and have receptors that are 
highly specific; for example, the high affinity IL-2 receptor has a dissociation 
constant of 5-20 x 10'12 M51. Given all of this, it is not surprising that the study 
of lymphokines is one the leading fields of research in cellular and molecular 
immunology. 
Interleukin 1 (IL-1) 
In the late 1940s it was first suggested that fever was initiated by a 
soluble factor produced and released by activated macrophages52. A protein 
with similar pyrogenic properties appropriately named endogenous pyrogen 
(EP) was demonstrated in the plasma of rabbits made febrile by injection of 
bacteria53. In the early 1970s Gery et al. reported that macrophages released 
one or more mitogenic substances which they called lymphocyte activating 
factor (LAF) that greatly potentiated the response of T lymphocytes to mitogens 
such as PHA but did not stimulate B cells in the absence of T cells54’55’56. 
Initial characterization of both EP and LAF revealed that agents which 
stimulated production of EP also stimulated LAF release, EP and LAF had 
similar kinetics for release, and that the two had nearly identical molecular 
weights and isoelectric points53. In the late 1970s and early 1980s 
Rosenwasser et al. reported that highly purified leukocytic pyrogen (also known 
as EP) replaced the soluble products of murine peritoneal exudate cells in the T 
cell proliferative response to antigen57 and enhanced the murine thymocyte 
proliferation response to PHA58 and thus established that EP and LAF were 
indeed the same molecule. 
. 
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Interleukin 1 was first purified by Blyden and Handschumacher who 
found that human LAP had an apparent molecular weight of approximately 
13,000 daltons59. Subsequent studies based on IL-1 obtained from human, 
mouse, and mouse macrophage cell lines have revealed a molecular weight of 
between 12,000 and 16,000 daltons60. Mizel and Mizel using culture fluid from 
the macrophage cell line P388D.1 first purified murine IL-1 to apparent 
homogeneity60. They noted a molecular weight of 14,000 daltons, three 
charged species which they termed a, (3, y, and a biological activity range within 
10"11 to 10’10 M. The complementary DNAs (cDNA) for both murine and human 
IL-1 have recently been cloned, expressed, and sequenced61 -62. The murine 
IL-1 cDNA codes for a polypeptide precursor of 270 amino acids61 with the 
biologically active polypeptides at least 127 amino acids long and derived from 
the carboxyl terminus of the 270 amino acid precursor63. Two distinct but 
distantly related cDNAs (IL-1 a and IL-1 (3) encoding for human IL-1 have been 
described62. Dower et al. have shown the IL-1 binds to a plasma membrane 
receptor with an apparent affinity of approximately 0.2-2 xIO'10 M and molecular 
weight of about 80,000 daltons64-65. Bird and Saklatvala66 , Dower et al. 67, 
and Kilian et al.68 have all independently shown that the IL-1 receptor on 
fibroblasts and on T cells binds both IL-1 a and IL-1 (3. 
In addition to its role as a mediator of the acute-phase response, IL-1 acts 
on a number of cells in the immune system including B cells and T cells69. 
Lipsky et al. using antiserum against human leukocytic pyrogen showed that IL- 
1 plays a necessary role in B cell proliferation and in the generation of 
immunoglobulin-secreting cells70. Howard et al. noted that IL-1 and IL-4 acted 
synergistically in the proliferation of anti-IgM activated B cells71. Gillis and 
Mizel observed that for certain T cell tumor lines IL-1 was necessary for the 
production of IL-226. Kaye et al. using the cloned helper T cell line D10 found 
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that IL-1 induced IL-2 receptor expression27. These findings implicate 11-1 as 
one of the key mediators of the immune response. 
INTERLEUKIN 2 (IL-2) 
Interleukin 2, originally termed TCGF,was first produced by stimulating 
normal human peripheral blood lymphocytes with PHA72. Shortly after the 
initial description of TCGF, several investigators reported the long term growth 
of normal human T cells73 and tumor-specific cytotoxic T cells74 using media 
supplemented with this factor. Using the tumor-specific cytotoxic T cell line 
(CTLL) Gillis et al. were able to develop a sensitive microassay for TCGF75. 
Biochemical characterization of IL-2 from mitogen-stimulated human, murine, 
and rat lymphocytes soon followed. Interleukin 2 from human and rat 
lymphocytes was found to have a molecular weight (on gel filtration) of 
approximately 15,000 daltons76 while murine IL-2 had a molecular weight of 
30,000 daltons77. Taniguchi et al. using a cDNA coding for human IL-2 showed 
that after processing mature human IL-2 contains 133 amino acids and a 
calculated molecular weight of 15,420.5 daltons78. The observation that murine 
IL-2 has an apparent molecular weight twice that of human and rat has been 
attributed to noncovalent dimerization of a 15,000 dalton subunit79. 
The findings that the mitogenic effect of IL-2 was strictly concentration 
dependent75 and that T cells activated by either lectins or antigens absorbed IL- 
2 in a cell concentration dependent fashion80 suggested that the binding and 
removal of IL-2 might be receptor mediated81. Robb et al. using internally 
radiolabeled IL-2 in a series of competitive binding experiments were the first to 
show that IL-2 interacted with activated T cells through a high affinity receptor51. 
With the monoclonal antibody anti-Tac Leonard et al. were able to partially 
purify and characterize the human IL-2 receptor82. They found that the receptor 
was a glycoprotein with a molecular weight of 47,000-53,000 daltons. Reports 
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of monoclonal antibodies directed against murine (7D4, AMT-13)83-84 and rat85 
IL-2 receptors soon followed. Both monoclonal antibodies against the murine 
IL-2 receptor precipitated a protein with an apparent molecular weight of 
50,000-60,000 daltons; however, only AMT-13 was able to inhibit IL-2 binding. 
These results suggest that AMT-13 binds to the active site on the murine IL-2 
receptor while 7D4 bind to a distal epitope or possibly another protein that is 
physically associated with the IL-2 receptor. Cloning of a cDNA encoding the 
human IL-2 receptor was independently undertaken by Leonard et al.86 and 
Nikaido et al.87. Both groups found two mRNAs hybridzing to the cDNA clone 
and a fairly identical sequence. At about the same time Robb et al. reported the 
presence of high and low affinity IL-2 receptors88. This finding helped explain 
the discrepancy that arose when quantitative binding studies using 
radiolabeled IL-2 and anti-Tac indicated that there were far more Tac binding 
sites than IL-2 binding sites. Robb et al. found that the low-affinity receptors had 
an association constant greater than 5,000 times lower than the initially 
described high-affinity receptor. Robb, in a definitive study which showed the 
conversion of low-affinity receptors to high-affinty receptors following fusion of 
cell membranes, that the same Tac protein can act either as a high or low 
affinity receptor89. Kondo et al. in an elegant synthesis of the literature on the 
IL-2 receptor have proposed that a binary complex between the IL-2 receptor 
and another protein would constitute a high-affinity receptor90. In their model, a 
high-affinity receptor is the ternary complex of IL-2, the IL-2 receptor, and a 
“converter" protein. 
Like interleukin 1 IL-2 has a number of roles in the immune response. 
Although primarily associated with T cell proliferation, IL-2 also directly or 
indirectly plays a role in the proliferation and maturation of other cell types79. 
Henney et al. found that IL-2 augmented natural killer activity91. Mond et al. 
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have shown that affinity purified IL-2 caused large B cells to proliferate92. 
Howard et al. noted that IL-2 induced certain antigen reactive T cell lines to 
secrete low levels of IL-493. Kasahara et al. using IL-2 were able to induce 
peripheral T cells to secrete IFN-y94. And Kelso et al., in a recent report on the 
regulation of GM-CSF production, observed that IL-2 preferentially induced 
certain T cell clones to secrete only GM-CSF as compared to GM-CSF and IL-3 
when stimulated with lectins such as Con A.95 
Interleukin 3 (IL-3) 
Interleukin 3 is one of two, the other being GM-CSF, colony stimulating 
factors which are active on early (pluri- or multipotential) precursors of 
hemopoietic stem cells96. It was initially identified as a lymphokine capable of 
inducing the enzyme 20a-hydroxysteroid dehydrogenase (a specific marker of 
mature T cells) in cultures of the splenic lymphocytes from athymic mice97. In 
addition to being secreted constitutively by the myelomonocytic leukemia cell 
line WEHI-3, T cells and T cell tumors produce IL-3 upon stimulation98. Using 
WEHI-3-conditioned media Ihle et al. purified IL-3 to apparent homogeneity99. 
They noted a molecular weight of 28,000 daltons by gel electrophoresis and an 
activity of 1.79 x 10'12 M. Fung et al. using mRNA from WEHI-3 cells were able 
to clone and sequence the cDNA coding for murine IL-3100. Sequence 
analysis of the cloned cDNA revealed that it coded for a precursor polypeptide 
of 166 amino acids. Yokata et al. cloning the cDNA for mast-cell growth-factor 
found a sequence identical to that of IL-3101. 
A broad range of biological activities have been attributed to IL-3 
including multi-colony stimulating factor, hematopoietic growth factor, burst- 
promoting activity, FDC-P cell line stimulating factor, mast cell growth factor, 
histamine-producing cell stimulating factor, and Thy 1-inducing activity100. 
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Interleukin 4 (IL-4) 
The existence of a T cell derived B cell growth factor was first implied 
from a study by Howard and her co-workers102. In that study normal mouse B 
cells were propagated with medium supplemented with a T cell-hybridoma- 
derived supernatant. Howard et al., using a phorbol myristate acetate (PMA) 
induced EL-4 supernatant, first identified a B cell growth factor (BCGF) as 
distinct from IL-2103. Ohara et al. using trimethyIsilyHcontrolied pore glass 
beads (TMS-CpG) and reverse-phase high-performance liquid chromatography 
(RP-HPLC) were able to partial purify IL-4 and noted an apparent molecular 
weight of 18,000 and 21,700 daltons when analyzed by isoelectric focusing and 
gel filtration-HPLC, respectively104. Using IL-4 purified in this manner Ohara 
and Paul were able to establish a rat-mouse hybridomas that secreted anti-IL-4 
antibodies (11B11 and 18F10)105. Grabstein et al. purified IL-4 to homogeneity 
and found a molecular weight of 18,400 daltons by gel electrophoresis106. The 
cDNA clone that encoded for murine IL-4 was isolated, expressed, and 
characterized independently by Noma et al.107 and Lee et al.108. Both groups 
noted that the murine IL-4 gene coded for a precursor polypeptide of 140 amino 
acids. Yokota et al. recently characterized the cDNA clone encoding for human 
IL-4109. They found that the human IL-4 gene encoded for a 153 amino acid 
polypeptide precursor and that on the genomic level human and murine IL-4 
shared extensive homology. Although there are presently no definitive reports 
concerning the IL-4 receptor, Mishra et al. have reported that a monoclonal 
antibody directed against the lymphocyte function-associated antigen 1 (LFA-1) 
a-chain, a cellular adhesion molecule, mimics some of the biological effects of 
IL-4 suggesting that LFA-1 may be the receptor for IL-4 or a receptor-associated 
molecule involved in IL-4 cell signaling110. 
. 
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Interleukin 4 possess a wide variety of biological activities. In addition to 
acting synergistically with IL-1 in enhancing proliferation of anti-IgM activated B 
cells, Noelle et al. have observed that IL-4 increased expression of class II MHC 
products on resting B cells111. Rabin et al. noted that a preculture with IL-4 
sped the entry of those cells into S phase when they were subsequently 
cultured with IL-4 and anti-IgM. They also observed that pretreatment of resting 
B cells with IL-4 resulted in a substantial increase in cell volume49. Vitetta et al. 
found that IL-4 in addition to being a B cell growth factor is also a B cell 
differentiation factor112. They noted that IL-4 induced the secretion of IgGI and 
inhibited the secretion of lgG3 in lipopolysaccharide (LPS)-stimulated B cells. 
Coffman et al. noted a similar finding concerning IgE production113-114. A 
recent report by Finkelman et al. concerning the suppression of an in vivo 
polyclonal IgE response by the anti-IL-4 antibody 11B11 further supports the 
observation made by Coffman et al.115. In addition to B cells, IL-4 has also 
been shown to promote the growth of T helper cell lines50-116, and to act as a 
costimulant with PMA on a heterogeneous population of resting T Cells117. 
Mosmann et al. have also observed that IL-4 costimulates with IL-3 to increase 
the proliferation of certain mast cell lines118. 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 
Like IL-3, GM-CSF is active on early precursors of hemopoietic stem 
cells. Lopez et ai. have recently reported that in addition to stimulating 
neutrophil progenitor cells GM-CSF also activates differentiated neutrophils119. 
They noted enhanced antibody-dependent, ceil mediated cytotoxicity when 
mature neutrophils were cultured with GM-CSF. Kelso et al. noted another 
difference between IL-3 and GM-CSF; whereas, IL-3 is solely secreted by 
activated T cells, GM-CSF is also produced by macrophages, fibroblasts, and 
endothelial cells95. Gough et al. using a partial NH2-terminal amino acid 
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sequence from purified mouse lung-conditioned medium were able to produce 
a cDNA clone which they used to isolate a unique gene encoding for GM- 
CSF120. They noted that the gene coded for a messenger RNA of 1,200 
nucleotides, a polypeptide of 118 amino acids, and had no structural similarity 
to 11-3. In addition to the aforementioned activities, Handman and Burgess 
reported that when peritoneal macrophages were treated with GM-CSF they 
were able to kill intracellular Leishmania tropica that were hitherto multiplying 
within the macrophage121. Dessein et al. noted eosinophil cytotoxicity was 
marked enhanced in the presence of GM-CSF122. Grabstein et al. noted that 
GM-CSF potentiated induction of antibody secretion by activating an accessory 
function of macrophages123 and induced macrophage tumoricidal activity124. 
Finally, Woods et al. have found that GM-CSF can induce proliferation in a 
TCGF dependent T cell line125. 
Interferon-gamma (IFN-y) 
Interferons are secreted proteins which have immunomodulatory and 
antitumor properties126. There are three major classes of interferons: IFN-a 
(leukocyte or fast) , IFN-{3 (fibroblast or slow), and IFN-y (immune)127. Unlike 
IFN-a or IFN-p, IFN-y is acid labile, does not cross-react with antisera prepared 
against IFN-a or IFN-p, and is generally produced in cultures by mitogenically 
stimulating lymphocytes126. Using a cDNA clone prepared from gel- 
fractionated IFN-y mRNA, Gray et ai. were able to isolate, characterize, and 
express the cDNA sequence encoding for the IFN-ygene126. They found that 
the DNA coded for a 166 amino acid polypeptide including a 20 amino acids 
signal peptide. Taking this into account Gray et al. calculated that the 
processed protein not accounting for post-translatioal modifications had a 
molecular weight of 17,110 daltons. 
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Interferon-gamma has a broad range of biological activities. Blalock et 
al. noted that IFN-y has both anticellular and antiviral activity128. Catalona et al. 
found that IFN-y is a potent stimulator of antibody-dependent cell-mediated 
cytotoxicity (ADCC) and of natural killer cytotoxicity129; while, Wallach noted 
that IFN-y induced resistance to the killing by NK cells130. A number of 
investigators have all independently shown that IFN-y induces expression of 
class II MHC products on macrophages131-132-133 and on endothelial cells134. 
Another immunomodulatory function has recently been ascribed to interferon-y. 
Coffman and Carty113 and Rabin et al.135 have observed that the IL-4 
polyclonal IgE response and the IL-4 response on resting B cells can be 
inhibited by IFN-y. Mond et al. have recently shown that IFN-y suppresses the 
IL-4 induced augmentation of class II MHC product expression136. Finally, 
Grabstein et al. noted that IFN-y also induced peripheral blood monocytes to 
exhibit tumoricidal activity against a malignant melanoma cell line124. 
Lymphotoxin (LT) 
Lymphotoxin is a lymphocyte derived glycoprotein possessing direct 
cytolytic and cytostatic activities for a variety of cells was first described by 
Ruddle and Waksman137. They noted that lymph node cells from inbred rats 
with delayed hypersensitivity to tuberculoprotein, bovine gammaglobulin, and 
egg albumin produced progressive destruction of monolayers of rat embryo 
fibroblasts in tissue culture138. Although some investigators have reported a 
number of different molecular weight lymphotoxins139, Gray et al. in cloning and 
expressing the cDNA encoding human lymphotoxin reported that lymphotoxin 
was encoded by a single gene140. They found that the lymphotoxin gene 
coded for a precursor polypeptide of 205 amino acids which after processing 
but before glycosylation was thought to have 171 amino acid and a molecular 
weight of 18,600 daltons. 
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A number of different biological activities has been ascribed to 
lymphotoxin. It has been shown to cause inhibition of tumor cell 
proliferation141. Sawada and Osawa implicated lymphotoxin as the effector 
molecule in T cell mediated cellular cytotoxicity142; while, Wright and Bonavida 
found that a lymphotoxin-like molecule mediated lysis of natural killer cell 
targets143. However, Green et al. recently readdressed this issue and found 
that human cytotoxic T cells produced cytotoxins that were antigenically distinct 
from lymphotoxin144. Kondo et al. observed that antiserum against 
lymphotoxin inhibited ADCC and hence suggested that lymphotoxin was the 
mediator of ADCC145. Stone-Wolff et al.146 and Lee et al.147 have both 
recently shown marked synergistic enhancement of cytotoxicity when 




The growth and proliferation of mammalian cells are controlled in part by 
polypeptide hormones found in the serum148. Malignant or transformed cells 
appear to require no or lower concentrations of growth-controlling factor(s) as 
compared with normal or untransformed cells148. It has therefore been 
suggested that cells could become malignant via the aberrant production of 
polypeptide growth-controlling factor(s) acting in an autocrine manner through 
functional cell membrane receptors resulting in uncontrolled proliferation149. 
Recently, the “autocrine hypothesis” has been further defined in that malignant 
transformation may be the result not only of excessive production, expression, 
and action of positive autocrine growth factors but also the failure of cells to 
synthesize, express or respond to specific negative growth factors that they 
normally release to control their own growth150. 
Interleukin 2, originally termed T cell growth factor, has been shown to 
promote the proliferation of any IL-2 receptor positive T cell79. It has been 
shown that the T helper cell line DIO apparently secretes large amounts of IL-2 
(as determined by its ability to stimulate an IL-2 dependent cell line and by the 
observation that its autocrine proliferation is inhibited by a monoclonal anti-IL-2 
antibody) upon crosslinking of its antigen-class II MHC products receptor yet 
fails to proliferate27-34. Furthermore, DIO cells have to been shown to both 
respond to IL-2 derived from the T cell hybridoma AOFS34 and to express 
functional IL-2 receptors27. Thus in the presence of both functional IL-2 and IL- 
2 receptors this clone fails to proliferate. 
The goal of the experiments described in this thesis is to determine the 
mechanisms involved in this paradox. The growth factor(s) found in the 
stimulated supernatants from DIO cells and AOFS cells will be further 
characterized in order to ascertain why these two supernatants have different 
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biological activities yet both apparently contain IL~2. It is possible that the 
supernatant from the transformed cell line contains a growth-factor(s) that 
is(are) absent from the normal cell lines' supernatant. Likewise, it is possible 
that the DIO supernatant has a negative growth-factor(s) absent from the AOFS 
supernatant that prevents its uncontrolled proliferation. 
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Materials and Methods 
Animals. The mice used in these experiments, BALB/cByJ and AKR/J, 
were obtained from The Jackson Laboratory. 
Cloned T-Cell Lines. The AKR/J cloned T-cell line D10.G4.1 (DIO) has 
been described extensively23-24-27-34. It is specific for the hen white protein 
conalbumin (Sigma Chemical Co. St. Louis, MO) in the context of l-Ak and also 
responds to the monoclonal anti-T cell receptor antibody 3D3 (see below). The 
BALB/cByJ cloned T cell lines 5.5 and 5.9.24 have been described in detail 
elsewhere151-152-153. They are specific for hen ovalbumin (Sigma Chemical 
Co. St. Louis, MO) and l-Ed or l-Ad, respectively. These cloned T cell lines were 
maintained at 37°C in a 5% C02 atmosphere by feeding with syngeneic 
mitomycin C-treated spleen cells and specific antigen (100 pg/ml) every one to 
three weeks in Click's EHAA medium154 (Irvine Scientific, Santa Ana, CA) 
supplemented with 10% fetal bovine serum (Irvine Scientific, Santa Ana, CA) 
and 5% TCGF-containing supernatant of concanavalin A (Con A) (Pharmacia 
Inc., Piscataway, NJ)-treated rat spleen cells155. Between feedings with spleen 
cells and antigen, the T cell lines were fed at intervals with the same medium. 
Antibodies. Monoclonal murine IgGI anti-DI0-receptor antibody (3D3). 
The monoclonal antibody was produced and assayed as described34. It was 
used as a saturated ammonium sulfate (SAS) precipitated, Protein A purified 
diluted ascitic fluid. 
Monoclonal rat IgGI anti-murine-BSF- 1/IL-4 antibody (11B11). 
Hybridoma cells were a kind gift from J. Ohara and W. E. Paul (National 
Institutes of Health, Bethesada, MD) and this antibody has been extensively 
described elsewhere105. Antibody was used as a SAS precipitated ascitic fluid 
at a final concentration of 1: 200. 
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Monoclonal rat lgG2a anti-murine-IL-2 antibody (S4B6). Hybridoma cells 
were a kind gift from T. Mosmann (DNAX Research Institute of Molecular and 
Cellular Biology, Palo Alto, CA) and this antibody has been extensively 
elsewhere118. Antibody was used as serum-free culture supernatant at a final 
concentration of 1: 4 unless otherwise noted. 
Culture Supernatants. Interleukin 1 Murine IL-1 was prepared as 
described27 by stimulating the murine macrophage cell line P388.D1 with 
1pg/ml of lipopolysaccharide (Difco Labs, Detroit, Ml) for twenty-four hours. 
Recombinant-derived murine IL-1 a. Murine IL-1 a was a kind gift of S. 
Gillis (Immunex Corp. Seattle, WA). 
Recombinant-derived human IL-2. Human IL-2 was purchased from 
AMGen Biologicals (Thousand Oaks, CA). 
Recombinant-derived murine IL-2 Murine IL-2 was a kind gift of S. Gillis 
(Immunex Corp. Seattle, WA). 
Affinity purified BSF-1/IL-4. A high titered, BSF-1/IL-4 containing 
supernatant was kindly provided by L. Greenbaum (Yale University School of 
Medicine, New Haven, CT). Briefly, DIO cells were incubated for twenty-four 
hours at a concentration of one million cells per milliliter in serum-free EHAA 
medium containing 1% HB101 (Hara Medium, Berkeley, CA) and 2.5pg/ml of 
Con A. Supernatants were collected and passed over an anti-BSF-1 /IL-4 
affinity column. The bound material was eluted with 0.1% trifluoracetic acid. Its 
biological activity was inhibited by a monoclonal anti-BSF-1/IL-4 antibody. 
Recombinant-derived murine Interferon-y. Murine IFN-y was a kind gift of 
the Genentech Inc. (San Francisco, CA). 
AOFS supernatants. The T cell hybridoma AOFS 21.10.9 was kindly 
donated by P. Marrack and J. Kappler (National Jewish Hospital, Denver, CO). 
Supernatants were obtained by incubating cells at an initial concentration of 5 
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xIO5 cell/ml with 2.5pg/ml of Con A in EHAA medium lacking serum for twenty- 
four hours. Con A Supernatants were then collected, filtered over a 0.22pm 
millipore filter (Millipore Corp., Bedford, MA).and neutralized with 20mg/ml of 
methyl a-D-mannoside (Sigma Chemical Co., St. Louis, MO). 
DIO supernatants/inhibitor supernatants. DIO cells at one hundred 
thousand (105) cells per milliliter were stimulated for twenty-four hours in Click’s 
EHAA medium containing 5% serum with either the monoclonal anti-receptor 
antibody 3D3 at 20ng/ml or Con A at 2.5pg/ml. Supernatant were collected and 
flitered over a 0.22pm millipore filter, and the Con A supernatants were 
neutralized with 20mg/ml of methyl a-D-mannoside. All assay using such 
supernatants contained 5mg/ml of methyl a-D-mannoside. Unless referred to 
otherwise 3D3 was used to generate the supernatants. 
Bioassays. Proliferation assays. Cells plus supernatants were incubated 
together in either lOOpI or 200pl volumes of Click's EHAA/5% fetal bovine 
serum in flat-bottom 96 well trays. After culture for twenty of forty-four hours at 
37°C in a 5%C02 atmosphere, 1 pCi (1 Ci= 37GBq) of tritiated-thymidine was 
added to each microculture. Four hours later, cells were harvested with a PHD 
harvester (Cambridge Technologies, Cambridge, MA), and incorporated 
tritiated-thymidine of triplicate cultures were determined. Standard deviations of 
mean CPM incorporated were <20% and have been omitted. 
IL-1 assay. IL-1 was assayed as previously described by comitogenesis 
of DIO cells and 3D327. Such supernatants caused no growth of DIO in the 
absence of and were without activity in the TCGF assay. 
TCGF assay. IL-2 and/or IL-4 was assayed by measuring the 
incorporation of tritiated-thymidine by the TCGF-dependent T helper cell line 
HT-2, initially described by Watson156. After twenty hours, microcultures of 104 
■ 
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cells were incubated for four hours with IpCi of tritiated-thymidine and 
subsequently harvested and mean CPM of triplicate cultures determined. 
Inhibitor assay. Inhibitor containing supernatants were incubated for 
forty-eight hours with twenty thousand (2 x 104) 5.5 cells in the presence of 0.5 
units of recombinant IL-2. Proliferation was measured by pulsing with 1 jiCi/well 
of tritiated-thymidine for the final four hours of the assay. Cells were 




The cloned murine T helper cell line DIO has previously been shown to 
secrete large amounts of a T cell growth factor (TCGF) when stimulated with a 
monoclonal antibody (3D3) specific to its T cell receptor complex27. DIO cells 
have also been shown to proliferate in response to an IL-2 rich AOFS 
supernatant34 and to recombinant IL-2. Flowever, when DIO cells are 
stimulated with 3D3 they fail to proliferate unless IL-1 is also added to the 
cultures (Table I). To further explore this observation, DIO cells were cultured 
with recombinant IL-2 and with a 3D3 stimulated DIO supernatant. As noted in 
Table 1, DIO cells only proliferated in response to recombinant IL-2. Given 
these paradoxical findings, the following experiments were performed in order 
to explain this phenomenon. 
Both DIO Supernatant and AOFS Supernatant Have TCGF Activity. 
When DIO cells are stimulated with 3D3 in a twenty-four hour culture they 
secrete a factor(s) which has TCGF activity as measured by bioassay of the 
supernatant on the TCGF dependent cell line HT-2 (Fig. 1). Likewise, when the 
T cell hybridoma AOFS is stimulated with the mitogenic lectin Con A a twenty- 
four hour supernatant also stimulates the proliferation of HT-2 cells. Thus, DIO 
supernatant and AOFS supernatant contain a factor(s) possessing TCGF 
activity. 
AOFS Supernatant Contains IL-2 and IL-4 While DIO Supernatant 
Contains Only IL-4. The preceding experiment revealed that both supernatants 
had TCGF activity. Given that HT-2 cells respond to both IL-2106, IL-450, and 
GM-CSF125 it was necessary to determine which factor(s) in each supernatant 
was causing the growth of the HT-2 cells. Using monoclonal antibodies with 
specificities against either IL-2 (Table II) or IL-4 each supernatant was tested. 
(Presently, there are no monoclonal antibodies specific for GM-CSF). 

Table I. Both DIO and HT-2 Cells Proliferate in Response to Recombinant IL-2 
While Only HT-2 Cells Proliferate in Response to DIO Supernatant. 
Stimulus D101 HT-22 
- 1030 563 
+3D33 3096 - 
+IL-14 1742 - 
+3D3+IL-1 53058 - 
+RIL-25 36987 178610 
+3D3-stimulated D10 S/N6 3903 97402 
1D10 cells at 20,000 cells/well were incubated in triplicate culture in the 
presence of the above stimuli for forty-eight hours. Proliferation was measured 
by pulsing with tritiated thymidine for the last four hours of the assay. Mean 
±SD (omitted from table) were calculated for each triplicate culture. 
2HT-2 cells at 10,000 cells/well were incubated in triplicate culture in the 
presence of the above stimuli for twenty-four hours. Proliferation was measured 
by pulsing with tritiated thymidine for the last four hours of the assay. Mean 
±SD (omitted from table) were calculated for each triplicate culture. 
320ng/ml of 3D3. 
435 P388D1 IL-1 rich supernatant. 
55.0 units of recombinant IL-2. 
6D10 cells at 105 cells/ml were stimulated with 20ng/ml of 3D3 for twenty-four 
























Supematant Concentration, % 
Figure 1: HT-2 cells at 10,000 cells/well were incubated in 
triplicate culture for twenty-four hours with varying 
concentrations of TCGF containing supernatants. 
Proliferation was measured by pulsing for the last four 
hours of the assay with lpCi/well of tritiated thymidine. 
Mean ±SD (<20%, omitted from figure) was calculated 





Table II. The Monoclonal Antibody S4B6 Inhibits the Proliferative Response of 
HT-2 Cells to Recombinant Murine Interleukin 2. 
Concentration of RIL-2 Control +S4B6 
1.25 Units 50060 37174 
0.08 Units 2268 137 
HT-2 cells at 10,000 cells per well were incubated in triplicate culture for twenty- 
four with murine recombinant IL-2 in the presence or absence of a 1:2 dilution of 
S4B6 culture supernatant. Proliferation was measured by pulsing with 
IjiCi/well of tritiated thymidine for the last four hours of the assay. Mean ± SD 
(<20%, omitted from table) was calculated for each triplicate culture. Response 
reported in ACPM. 
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Treatment of the AOFS supernatant with either the monoclonal antibody to IL-2 
or to IL-4 resulted in decreased proliferation by the HT-2 cells (Fig. 2). When 
treated with both antibodies together the TCGF containing activity in the AOFS 
supernatant was essentially removed. When the DIO supernatant was cultured 
with the same panel of monoclonal antibodies, only treatment with the 
monoclonal antibody specific to murine IL-4 resulted in a decreased 
proliferative response by the HT-2 cells (Fig. 3). Quantification of the TCGF 
activity in the AOFS supernatant revealed that it contained 25 units/ml of IL-2 
and approximately 8 units/ml of IL-4; while, the TCGF activity of DIO 
supernatant was due to the presence of about 45 units/ml of IL-4. In summary, 
AOFS supernatant contains both IL-2 and IL-4 while DIO supernatant contains 
only IL-4. 
DIO Supernatant Fails To Induce Proliferation of DIO Cells. Given that 
both the AOFS supernatant and the DIO supernatant caused the T helper cell 
line HT-2 to proliferate, the question as to whether both supernatants could 
cause growth in another T helper cell line was readdressed. Both an AOFS 
supernatant and a DIO supernatant were titrated on Di0 cells. The AOFS 
supernatant caused proliferation on DIO that approached background when 
diluted (Fig. 4). On the other hand, DIO supernatant which caused analogous 
proliferation to that of the AOFS supernatant of HT-2 cells induced only minimal 
proliferation of DIO cells (Table I and Figs. 1 and 4). In summary, although DIO 
supernatant contains a T cell growth factor it nonetheless failed to induce a 
proliferative response on DIO cells. 
The question that naturally arises from these observations is: what 
prevents the TCGF found in DIO supernatant from acting upon DIO cells? A 
preliminary answer emerges when one closely examines the effects on DIO 


























AOFS Supernatant (% Cone.) 
Figure 2: HT-2 cells at 10,000 cells/well were incubated in 
triplicate culture for twenty-four hours with varying 
concentrations AOFS supernatant in the presence or 
absence of a variety of monoclonal antibodies. 1 IB 11 is a 
monoclonal antibody with specificity against murine 
BSF-l/IL-4. S4B6 is a monoclonal antibody with 
specificity against murine IL-2. Proliferation was 
measured by pulsing for the last four hours of the assay 
with lpCi/well of tritiated thymidine. Mean ±SD (<20%, 
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+11B11 
-*■ +S4B6 
DIO S/N (% Cone.) 
Figure 3: HT-2 cells at 10,000 cells/well were incubated in 
triplicate culture for twenty-four hours with varying 
concentrations D10 supernatant in the presence or absence 
of a variety of monoclonal antibodies. 1 IB 11 is a 
monoclonal antibody with specificity against murine 
BSF-l/IL-4. S4B6 is a monoclonal antibody with specificity 
against murine IL-2. Proliferation was measured by pulsing 
for the last four hours of the assay with lpCi/well of 
tritiated thymidine. Mean ±SD (<20%, omitted from figure) 






















Supernatant Concentration, % 
Figure 4: DIO cells at 20,000 cells/well were incubated in 
triplicate culture for forty-eight hours with varying 
concentrations of TCCF containing supernatants. 
Proliferation was measured by pulsing for the last four 
hours of the assay with lpCi/well of tritiated thymidine. 
Mean ±SD (<20%, omitted from figure) was calculated 





cause substantial growth of DIO cells; however, when the supernatant is diluted 
DIO cells begin to show an increasing proliferative response. These findings 
suggest that there is an inhibitor in DIO supernatant which is not present in 
AOFS supernatant that prevents autocrine stimulation. 
DIO Supernatant Inhibits the Response of Other Cloned T Cell Lines to 
IL-2. In order to determine whether the inhibitory nature of DIO supernatant 
was unique to the DIO cell line other T helper cell lines were tested for their 
ability to respond to DIO supernatant, recombinant IL-2, and a mixture of both. 
The BALB/c cloned T cell line 5.5 responds well to recombinant IL-2 but not to 
DIO supernatant (Fig. 5). Furthermore, DIO supernatant significantly inhibits 
the response of these cells to recombinant IL-2. Analogous results were seen 
with another BALB/c T cell clone 5.9.24 (Fig. 6). In summary, DIO supernatant 
can significantly inhibit the proliferative response to recombinant IL-2 on a 
number of different T helper cell lines. 
These experiment further defined some of the cellular properties of the 
inhibitory factor (s) in DIO supernatant. (For simplicity, the inhibitory factor (s) in 
DIO supernatant shall now be referred to as Inhibitor). Given that 3D3 does not 
react specifically with either 5.5 or 5.9.24, and that analogous results were 
obtained whether DIO was stimulated with either 3D3 or Con A (data not 
shown), the inhibitory substance is not 3D3. Furthermore, as the T helper cell 
clones DIO and 5.5 differ in antigen specificity and MHC restriction, and are 
derived from mice differing at MHC and other loci, Inhibitor is apparently not 
genetically restricted in its action on other cells and thus is distinct from most 
known suppressor factors. 
Secretion of Inhibitor by DIO is Stable Over Time. To determine whether 
or not secretion of Inhibitor was the result of transient cell culturing conditions, 
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Inhibitor (Cone.) 
X 
-O INH S/N 
-#■ +RIL-2 
X=0.5U RIL-2 
Figure 5: 5.5 cells at 20,000 cells/well were incubated in 
triplicate culture for forty-eight hour with varying concentrations 
of Inhibitor supernatant in the presence or absence of 0.5 Units 
of recombinant IL-2. Proliferation was measured by pulsing 
with IpCi of tritiated thymidine for the last four hours of the 
assay. Mean ±SD (<20%, omitted from figure) was calculated 
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X=0.5U RIL-2 
Inhibitor Supernatant (Cone.) 
Figure 6: 5.9 cells at 20,000 cells/well were incubated in 
triplicate culture for forty-eight hours with varying 
concentrations of Inhibitor supernatant in the presence of 0.5 
Units of recombinant IL-2. Proliferation was measured by 
pulsing with IpCi/well of tritiated thymidine for the last four 
hours of the assay. Mean ±SD (<20%, omitted from figure) 
was calculated for each triplicate culture. 
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approximately three years. Although the responsiveness of 5.5 cells to 
recombinant IL-2 has apparently changed Inhibitor can still significantly inhibit 
the proliferative response to IL-2 on the 5.5 cells (Fig. 7). Thus Inhibitor was not 
the result of transient cell culturing conditions. 
Interferon-y is Not Inhibitor. As previously discussed, IFN-y has both 
immunoregulatory and anticellular activities. Given that both Inhibitor and IFN-y 
have apparent antiproliferative properties and are T helper cell products it was 
necessary to determine whether Inhibitor is IFN-y. A titration of recombinant 
IFN-y in the presence of recombinant IL-2 did not result in diminution of the IL-2 
proliferative response (Fig. 8). This observation combined with those of 
Mosmann et al.44 and Killar et a!.46 that IL-4 producing T helper cell lines do not 
secrete IFN-y provides definitive evidence that Inhibitor is not IFN-y. 
Interleukin 4 is Not Inhibitor. It may be argued that on theoretical grounds 
IL-4 may be the Inhibitor. Given that IL-2 and IL-4 both activate HT-2 cells it is 
possible (although not probable) that they use the same or similar receptors. 
This being correct, it would not be unreasonable to assume that these ligands 
would have different affinities for this presumed receptor. If so, IL-4 binding this 
presumed receptor may not result in activation but may occupy binding sites 
such that IL-2 can not signal the cell. Therefore, if the concentration of IL-4 is 
much higher than that of IL-2, IL-4 may act as an inhibitor of IL-2. To determine 
the plausibility of this assumption varying concentrations of IL-4 were cultured 
with IL-2 (Fig. 9). The results here show that IL-4 synergizes with IL-2 resulting 
in the proliferation of 5.5 cells. The finding of Robb et al.51 that the IL-2 receptor 
has a very high affinity for IL-2 and the observation by Ohara and Paul105 that 
anti-IL-2 receptor antibodies failed to block the biological activity of IL-4, 
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X=0.5U RIL-2 
Figure 7: 5.5 cells at 20,000 cells/well were incubated in 
triplicate culture for forty-eight hour with varying 
concentrations of Inhibitor supernatant in the presence of 0.5 
Units of recombinant IL-2. Proliferation was measured by 
pulsing with lpCi of tritiated thymidine for the last four hours 
of the assay. Mean ±SD (<20%, omitted from figure) was 
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Figure 8: 5.5 cells at 20,000 cells/well were incubated in 
triplicate culture for forty-eight hour with varying 
concentrations of recombinant interferon- gamma in the 
presence or absence of 0.5 Units of recombinant IL-2. 
Proliferation was measured by pulsing with lpCi/well of 
tridated thymidine for the last four hours of the assay. Mean 






















BSF-l/IL-4 (dilution of stock solution) 
Figure 9: 5.5 cells at 20,000 cells/well were incubated in 
triplicate culture for forty-eight hour with varying concentrations 
of affinity purified BSF-l/IL-4 in the presence or absence of 
0.5 Units of recombinant IL-2. Proliferation was measured by 
pulsing with l|iCi/well of tritiated thymidine for the last four 
hours of the assay. Mean ±SD (<20%, omitted from figure) 






DIO Expresses Functional IL-1 Receptors. Kaye et al.34 noted that when 
DIO cells were stimulated with 3D3, the presence of either accessory cells or IL- 
1 was necessary to insure cellular proliferation. This observation led Kaye et al. 
to propose that two distinct events, namely receptor cross linking and 
stimulation with IL-1, must take place in order for cellular proliferation to occur. 
The question that logically follows from this is: by what mechanism does 
receptor cross linking and stimulation with IL-1 lead to proliferation of DIO? As 
shown in Table I and Fig. 3, activation of DIO in the absence IL-1 results in 
secretion of IL-4 but no growth and IL-1 alone does not induce DIO to 
proliferate. However, if DIO cells are cultured in the presence of both DIO 
supernatant (as a source of IL-4) and IL-1 proliferation occurs (Fig. 10). In order 
to rule out the possibility that this proliferation was due to carryover 3D3, an 
identical experiment using a Con A induced DIO supernatant was performed. 
Analogous findings were noted (data not shown), thus proliferation was not 
caused by carryover 3D3 but the result of synergy between IL-1 and the 
factor(s) found in DIO supernatant. In a similar experiment done by Dr. C. 
Janeway, preculture of DIO cells with IL-1 followed by subsequent 3D3 
stimulation also resulted in proliferation. The conclusions to be drawn from 
these experiments are that the factor(s) contained in DIO supernatant and IL-1 
are synergistic on DIO cells, and that under its current cell culturing conditions 
DIO expresses functional IL-1 receptors. 
Autocrine Proliferation of DIO is an IL-4 Mediated Process. The finding 
that DIO supernatant caused HT-2 cells to proliferate, combined with the 
observation that the proliferative response of DIO to 3D3 and IL-1 was greatly 
reduced by a monoclonal antibody with a reported specificity against murine IL- 
2, led to the conclusion that DIO secreted IL-227-34. However, using 






















Figure 10: DIO cells at 20,000 cells/well were incubated in 
triplicate culture for forty-eight hours with varying 
concentrations of Inhibitor supernatant in the presence or 
absence of an IL-I rich P388D.1 supernatant. Proliferation 
was measured by pulsing for the last four hours of the assay 
with IpCi/well of tritiated thymidine. Mean ±SD (<20%, 






2 and IL-4, it was determined that DIO supernatant contains only 11=4 (Fig. 3) 
and that the proliferative response of DIO to 3D3 and IL-1 was IL-4 and not IL-2 
mediated (Table III). Thus, the autocrine proliferation of DIO is an IL-4 mediated 
process. 
Interleukin 1 Augments the Response of DIO to IL-4. Given that 
autocrine proliferation in the DIO system is IL-4 mediated and that DIO 
supernatant and IL-1 are synergistic on DIO it appears that IL-1 is necessary for 
optimum IL-4 function. To test this hypothesis DIO cells were incubated with 
various concentrations of affinity purified IL-4. In the absence of recombinant 
murine IL-1 minimal proliferation of DIO occurred (Fig. 11). Flowever, when 
affinity purified IL-4 was cultured in the presence of recombinant murine IL-1 
there was substantial proliferation of DIO. To test whether the proliferation of 
DIO was due to IL-4 and not some other factor a monoclonal antibody with 
specificity against murine IL-4 was used as an internal control. As shown in Fig. 
11 the proliferation of DIO was substantially diminished in the presence of the 
antibody. An appealing explanation for this observation is that IL-1 is necessary 
for the expression of IL-4 receptors. 
Interleukin 1 Augments Response of HT-2 to IL-4. Given that FIT-2 cells 
respond to IL-450 and the observation that IL-1 augments the response to IL-4, it 
was thought that IL-1 also may augment the IL-4 response on the HT-2 cell line. 
As shown in Fig. 12 HT-2 cells behave analogously to DIO. Thus, IL-1 
augments the response of HT-2 cells to IL-4. 
Interleukin 1 Augments the Response of DIO But Not HT-2 to IL-2. Kaye 
et al.27 have previously shown that IL-1 is necessary for IL-2 receptor 
expression on DIO. Figure 13 shows that IL-1 augments the response of DIO 
cells to IL-2, thus confirming the finding of Kaye et al. Figure 13 also shows that 
the anti-IL-4 antibody 11B11 inhibits the proliferative response of DIO to IL-1 
\ 
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Table III. Proliferation of the Cloned Helper T Cell Line D10 is an Interleukin 4 
not an Interleukin 2 Mediated Process. 




+ - - - - 122 943 2711 
+ + - - - 871 1704 8636 
+ - + - - 1049 3672 7331 
+ + + - - 14643 59548 49040 
+ + + + - 12814 57850 47100 
+ + + - + 3165 6034 23762 
1 2 x 104 cells/well. 
2 20ng/ml of 3D3. 
3 3% P388D1 IL-1 rich supernatant. 
4 S4B6 (anti-IL-2) at 1:4 culture supernatant. 
5 11B11 (anti-IL-4) at 1:200 SAS cut ascites. 
6 Mean CPM of tritiated thymidine incorporation of triplicate cultures, pulsed for 

























Figure 11: DIO cells at 20,000 cells/well were incubated in 
triplicate culture for forty-eight hours with varying 
concentrations of affinity purifird BSF-l/IL-4 in the 
presence or absence of recombinant murine IL-1 (RIL-1) 
and in the presence of RIL-1 and 11B11. 1 IB 11 is a 
monoclonal antibody with specificity against BSF-l/IL-4 
Proliferation was measured by pulsing for the last four 
hours of the assay with lpCi/well of tritiated thymidine. 
Mean ±SD (<20%, omitted from figure) was calculated for 























Figure 12: HT-2 cells at 10,000 cells/well were incubated in 
triplicate culture for twenty-four hours with varying 
concentrations of affinity purified BSF-l/IL-4 in the presence 
or absence of an IL-1 rich P388D.1 supernatant. Proliferation 
was measured by pulsing for the last four hours of the assay 
with lpCi/well of tritiated thymidine. Mean ±SD (<20%, 



























Recombinant IL-2 (Units) 
Figure 13: DIO cells at 20,000 cells/well were incubated 
in triplicate culture for forty-eight hours with varying 
concentrations of murine recombinant IL-2 (RIL-2) in 
the presence or absence of recombinant murine IL-1 
(RIL-1) and in the presence of RIL-1 and 11B11. 
1 IB 11 is a monoclonal antibody with specificity against 
BSF-l/IL-4 Proliferation was measured by pulsing for 
the last four hours of the assay with lfiCi/well of 
tritiated thymidine. Mean ±SD (<20%, omitted from 




plus IL-2. A possible explanation for this observation is that IL-2 causes DIO to 
secrete IL-4 which in turn accounts for part of the proliferative response. This is 
similar to the observation of Howard et al.93 who noted a similar finding with 
their antigen reactive T cell clones. Interleukin 1 does not augment the 
response of HT-2 cells to IL-2 (Fig. 14). A likely explanation for this 
phenomenon is the fact that HT-2 cells constitutively express a very high 























Figure 14: HT-2 cells at 10,000 cells/well were incubated in 
triplicate culture for twenty-four hours with varying 
concentrations of recombinant IL-2 in the presence or absence 
of an IL-1 rich P388D.1 supernatant. Proliferation was 
measured by pulsing for the last four hours of the assay with 
ljlCi/well of tritiated thymidine. Mean ±SD (<20%, omitted 






The cloned murine T helper cell line D10.G4.1 was initially described by 
Kaye et al. 34. They noted that stimulation with an anti-receptor monoclonal 
antibody resulted in secretion of lymphokines including a factor with TCGF 
activity. Further characterization of this factor revealed that it caused the TCGF 
dependent line HT-2 to proliferate. In addition, the anti-IL-2 antibody prepared 
by Gillis and Henney157 was shown to inhibit the proliferation of DIO in 
response to 3D3 and IL-127. Taken together these observations provided 
convincing evidence that stimulation of DIO resulted in the release of IL-2. 
However, evidence to the contrary soon followed. Using an anti-IL-2 antibody 
prepared by Smith et al.158 it was observed that the TCGF activity of DIO 
supernatant could not be inhibited while that of AOFS supernatant could (JBH, 
unpublished observations). This finding combined with those presented here 
that the TCGF activity in DIO supernatant can be blocked by monoclonal 
antibodies to IL-4 but not to IL-2 strongly suggests that the TCGF activity in DIO 
supernatant is due to IL-4 and not IL-2. We are currently using probes for IL- 
2mRNA and IL-4mRNA to definitively determine that DIO does not produce IL-2. 
These findings also suggest that the antibody produced by Gillis and Henney 
might not have been an anti-IL-2 antibody but in actuality may have been an 
anti-IL-4 antibody. 
The paradox of why DIO to fails to proliferate in response to high levels 
of TCGF was also examined. The finding that a diluted DIO supernatant 
caused a greater proliferative response than a more concentrated one 
suggested one reason that DIO did not proliferate in response to high levels of 
TCGF was due to the presence of an inhibitor. It appeared that the inhibitory 
effect of this factor could be overcome by adding IL-1. The observations that 
DIO supernatant inhibited the response of other cell lines to IL-2 further 
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supported this notion. Partial purification of this factor by Horowitz et al.159 
revealed that it was heat and acid stable and had a molecular weight of 
approximately 12,000 daltons. It was also noted that purification of Inhibitor 
significantly increased its inhibitory action. As shown here Inhibitor is not IFN-y 
nor is it IL-4. Given that DIO does not secrete lymphotoxin160, Inhibitor is not 
lymphotoxin. The observation that IL-1 can reverse can the action of Inhibitor 
makes it highly unlikely the Inhibitor is the so-called “inhibitor of DNA synthesis” 
described by Namba and Waksman161. They found the action of their factor 
completely irreversible by thirty hours while in the presence of IL-1 and DIO 
supernatant DIO cells are synthesizing DNA, as measured by incorporation of 
tritiated-thymidine, forty-eight hours after initial exposure to Inhibitor. 
A number of other investigator have reported the existence of factors 
inhibiting il-2162'163,164,165_ Hardt et al. reported the presence of an IL-2 
inhibitor in the sera of normal mice but not in the sera of athymic mice162. They 
found this inhibitor to be neither antigen specific nor MHC restricted. In 
addition, they noted of molecular weight of about 50,000 daltons. Although the 
biologic activity of this IL-2 inhibitor is similar to Inhibitor it differs in that in it 
appeared to be produced by Lyt-23+ cells and it had an apparent molecular 
weight of 50,000 daltons. 
Kramer and Koszinowski found that Con A activated spleen cell 
produced IL-2 and factor(s) that inhibited proliferation of T cells to alloantigen 
and the generation of cytotoxic T cells from their precursors163. Their factor 
also inhibited the release of IL-2 from T cells; however, it did not affect the IL-2 
mediated growth of T cell blasts. Given that Inhibitor activity is measured by its 
ability to suppress proliferation due to IL-2 it is most unlikely that their factor and 
Inhibitor are the same. 
■ 
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A factor that was secreted by cultured glioblastoma cells and was 
capable of inhibiting the response of cloned T cells line to IL-2 in addition to 
inhibiting the proliferation of a neuroblastic cell line whose growth was not IL-2 
dependent was reported by Fontana et al.164. They also noted a molecular 
weight of 97,000 daltons. The fact that this factor inhibited the proliferation of a 
cell line that was not IL-2 dependent suggests that this factor may be a non¬ 
specific growth suppressor. This combined with its high molecular weight argue 
against this molecule and Inhibitor being the same. 
Lastly, Honda et al. have recently described an IL-2 inhibitor produced by 
Con A stimulated spleen cells165. They found that it was produced by Ly-1 + 
and Ly-2+ T cells. Additionally, they noted that it had a molecular weight of 
10,000 to 12,000 daltons and that no inhibitor activity could be detected in the 
supernatants of Con A stimulated spleen cells until day three. Although 
Inhibitor and this factor have similar molecular weights they differ in that differ 
markedly in their release kinetics; Inhibitor secretion occurs shortly (within 
twenty-four hours) after stimulation of D10 while Honda et al. find no detectable 
inhibitor activity until day three post stimulation. However, it is possible that the 
differences in release kinetics are due to the fact that D10 is not a resting T cell. 
Whether these two factors are the same or different remains unknown. 
The existence of an inhibitor to IL-2 is not surprising In fact it would help 
explain why in vivo IL-2 is only effective in close proximity to the secreting cells. 
Furthermore, it seems logical that a system, like the immune system, which 
depends upon rapid and specific activation of only a very limited number of 
cells would secrete factors that activate and inhibit other immune cells. Liao et 
al. recent description an inhibitor of IL-1 in the urine of febrile patients would 
support this contention166. The finding that D10 does not secrete IL-2 but IL-4 
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raises the question of what role Inhibitor plays in IL-4 mediated proliferation. 
This question is currently being investigated. 
The finding that the IL-4 dependent cell line DIO requires IL-1 in order to 
proliferate in response to IL-4 although not directly made by Kaye et al. could 
have been implied from their previously published reports27-43. As previously 
noted, Kaye et al. reported that when DIO cells are stimulated with 3D3 and IL-1 
there is at least a ten-fold increase in 7D4 binding protein expressed on the cell 
surface as analyzed by FACS. Using radiolabeled IL-2 it was determined that 
IL-1 results in a two-fold increase in high affinity IL-2 receptors (R. Robb and 
JBH, unpublished observations). Thus, IL-1 has definitively been shown to 
increase the number of high affinity IL-2 binding sites on DIO. Given that DIO 
does not secrete IL-2 the question that naturally arises is: what function do the 
high affinity IL-2 receptors have on DIO? The observation that stimulation of 
DIO with IL-2 results in secretion of IL-4 in addition to proliferation provides at 
least a partial answer to that question. Although the relative contributions of IL- 
2 and IL-4 on DIO proliferation is difficult to determine, it appears that IL-2 
results in at least some degree of proliferation independent of IL-4. 
The observations that IL-4 mediated proliferation is augmented by or 
requires IL-1 differs from those made by Hu-Li et al.116. Using a heterogeneous 
population of resting T cells from peripheral lymph nodes they found that PMA 
along with IL-4 were comitogenic for resting T cells. They noted that neither 
PMA nor IL-4 resulted in the proliferation of resting T cells, that IL-1 did not 
synergize with either PMA or IL-4 to result in T cell proliferation, and that T cells 
precultured with either PMA or IL-4 failed to respond to subsequent culture with 
PMA or IL-4 but did respond subsequent culture with both PMA and IL-4. 
Although these observations appear incompatible with the aforementioned 
finding that IL-1 is required for or augments IL-4 mediated proliferation they may 
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not actually be so. The finding that IL-1 and IL-4 are not comitogenic for resting 
T cells is not surprising. Currently there are no published reports suggesting 
that resting T cells express functional receptors for IL-1. Because of its ability to 
replace accessory cells in Con A induced IL-2 secretion and IL-2 receptor 
expression by L3T4+T cells, PMA at lOng/ml is considered by some 
investigators to be functionally equivalent to IL-1167. If this assumption is 
correct, it is possible that the reason why IL-4 and PMA are synergistic for 
resting T cells is that PMA is acting as an IL-1 analog, and thus increasing IL-4 
receptor expression. The observation by Hu-Li et al. that resting T cells 
pretreated with PMA fail to proliferate when subsequently treated with IL-4 is 
also contrary to our findings. Given that they pretreated their T cells with 1 ng/ml 
of PMA and used a ten-fold higher concentration of PMA in their IL-4 plus PMA 
costimulation experiments, it is possible that at a concentration of 1 ng/ml PMA 
does not act as an IL-1 analog. Taking all of the above into consideration, the 
findings of Hu-Li et al. are not necessarily inconsistent with ours. We are 
currently involved in competitive binding experiments to definitively prove that 
IL-1 induces the expression of IL-4 receptors. 
The finding that IL-1 and IL-4 are synergistic on HT-2 cells is most 
intriguing. The HT-2 cell line is unlike most other cloned murine T helper cell 
lines in that it is strictly dependent on TCGF and does not require antigen for its 
growth156. Furthermore, this cell line constitutively expresses a very high 
number (>10,000) of high affinity receptors (R. Robb personal communication). 
The ability of the cell line to respond to IL-1 and IL-4 argues that HT-2 cells 
maintain at least some degree of control over lymphokine receptor expression 




The findings that DIO ceils could be pretreated with IL-1 and then be 
subsequently stimulated to maximal proliferation with only 3D3 suggests that 
“resting” DIO under the currently employed cell culturing conditions expresses 
IL-1 receptors. Previous experiments have demonstrated that “resting” DIO 
expresses about 1,000 high affinity IL-2 receptors (R. Robb and JBH, 
unpublished observations). Additionally, it appears that “resting” DIO does not 
express significant numbers of IL-4 receptors; however, stimulation with IL-1 in 
the presence of IL-1 receptor most probably induces IL-4 receptor expression. 
Thus it appears that DIO is unlike resting T cells in that it expresses both IL-1 
and IL-2 receptors. These findings make the DIO cell line ideal for studying 
lymphokines given the presence of lymphokine receptors on its plasma 
membrane. 
In summary, it appears that there are at least two possible explanations 
of why DIO fails to proliferate in response to 3D3. The first explanation is that in 
addition to IL-4 DIO produces an inhibitor of IL-2 and possibly IL-4. Another 
reason for the failure of DIO to grow in response to apparently high levels of IL- 
4 may reside in the observation that DIO does not express significant numbers 
of IL-4 receptors. The relative contribution each plays has yet to be definitively 
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